Evidence map›Paper›PMID 36145486›Full record

ArticlePathogens (Basel, Switzerland)2022

Characteristics of COVID-19 Infection in a Hospitalized Autoimmune Hepatitis Patient.

Vanessa Duarte da Costa, Wilian Jean Wiggers, Claudia Alexandra Pontes Ivantes, Rodrigo Jardim Monteiro da Fonseca, Alberto Martín Rivera Dávila, Otacilio C Moreira, Beatriz Iandra da Silva Ferreira, Vanessa Salete de Paula, Lucas Lima da Silva, Alanna Calheiros Santos and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Vanessa Duarte da CostaBrazilian Reference Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
Wilian Jean WiggersService of Gastroenterology, Hepatology and Liver Transplantation, Hospital Nossa Senhora das Graças, R. Alcides Munhoz, 433, Mercês, Curitiba 80810-040, Brazil.
Claudia Alexandra Pontes IvantesService of Gastroenterology, Hepatology and Liver Transplantation, Hospital Nossa Senhora das Graças, R. Alcides Munhoz, 433, Mercês, Curitiba 80810-040, Brazil.ORCID 0000-0001-5422-557X
Rodrigo Jardim Monteiro da FonsecaComputational and Systems Biology Laboratory, Graduate Program in Biodiversity and Health, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.ORCID 0000-0002-0943-5356
Alberto Martín Rivera DávilaComputational and Systems Biology Laboratory, Graduate Program in Biodiversity and Health, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
Otacilio C MoreiraMolecular Virology Laboratory, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
Beatriz Iandra da Silva FerreiraMolecular Virology Laboratory, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
Vanessa Salete de PaulaMolecular Virology Laboratory, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
Lucas Lima da SilvaBrazilian Reference Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
Alanna Calheiros SantosBrazilian Reference Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.
Livia Melo VillarBrazilian Reference Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil.ORCID 0000-0001-7644-8969
Fundação Oswaldo Cruz · BRHospital Nossa Senhora das Graças · BR

Funding

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro 204.197/2021National Council for Scientific and Technological Development 315967/2021-8Oswaldo Cruz Foundation VPPCB-005-FIO-20-2-52
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a major public health worldwide. Hepatic dysfunction has been seen in patients with COVID-19 and could be related to a viral cytopathic effect, an exacerbated immune reaction, or drug-induced liver damage. Currently, routine modification of immunosuppressive therapy in patients with autoimmune hepatitis (AIH) before and after SARS-CoV-2 infection remains an important topic to be discussed. However, there is little evidence about this thematic to support any recommendation. Here, we described a case report in which the use of an immunosuppressive drug by a patient with diagnosed AIH might have influenced the COVID-19 clinical course with altered laboratory hematological and biochemical parameters during infection.

Indexed as

autoimmune hepatitisCOVID-19SARS-CoV-2

Identifiers

PMID36145486
PMCPMC9501835
OpenAlexW4296046947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.